Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban
What is known and objective The 4‐factor prothrombin complex concentrate (4F‐PCC) may be used to emergently achieve haemostasis in patients on anticoagulation prior to surgery. Limited data exist using the intraosseous route of administration of 4F‐PCC in patients taking factor Xa inhibitors. Case d...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2020-06, Vol.45 (3), p.577-579 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 579 |
|---|---|
| container_issue | 3 |
| container_start_page | 577 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 45 |
| creator | Ratliff, Patrick Nutley, Kaitlin Schroeder, William Cottingham, Lauren |
| description | What is known and objective
The 4‐factor prothrombin complex concentrate (4F‐PCC) may be used to emergently achieve haemostasis in patients on anticoagulation prior to surgery. Limited data exist using the intraosseous route of administration of 4F‐PCC in patients taking factor Xa inhibitors.
Case description
We describe a case of a 69‐year‐old female receiving oral apixaban that was successfully administered 4F‐PCC using intraosseous access prior to emergent surgery to obtain haemostasis intraoperatively.
What is new and conclusion
Intraosseous access may be a viable route of administration for 4F‐PCC in patients receiving factor Xa inhibitors to achieve haemostasis when necessary.
We present a case of a 69 year old female on chronic oral anticoagulation with apixaban in need of emergent surgery. Adequate peripheral intravenous access could not be obtained in a timely manner necessitating the use of 4‐factor prothrombin complex concentrate via the intraosseous route. The intraosseous route may be a viable option to achieve hemostasis effectively and safely. |
| doi_str_mv | 10.1111/jcpt.13094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2397641048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2397641048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3604-616e8cb7bb1de3f98f15eb3076e1127bda73bbe230652865ab8ad654e2eec6f23</originalsourceid><addsrcrecordid>eNp9kMtKAzEUhoMoWi8bH0AC7oSpucwk06UUrwi6qOshyZzRlM6kJhltwYWP4DP6JKZWXZrND-d8_OF8CB1SMqTpnU7NPA4pJ6N8Aw0oF0XGJCWbaECYGGW5ZHIH7YYwJYQIyfg22uG0JAWjZIDerrvolQsBXB-wqlvb2ZAm0boOuwbnn-8fjTLReTz3Lj5512rbYePa-QwWKTsDq4YIaW8TFR2GFvxjmuLQp_RLrJoIHnswYF9s94jV3C6UVt0-2mrULMDBT-6hh4vzyfgqu727vB6f3WaGC5JnggoojZZa0xp4MyobWoDmRAqglEldK8m1BsaJKFgpCqVLVYsiBwZgRMP4Hjpe96YTnnsIsZq63nfpy4rxkRQ5JXmZqJM1ZXzy4aGp0kWt8suKkmolulqJrr5FJ_jop7LXLdR_6K_ZBNA18GpnsPynqroZ30_WpV8XNIzw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397641048</pqid></control><display><type>article</type><title>Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Ratliff, Patrick ; Nutley, Kaitlin ; Schroeder, William ; Cottingham, Lauren</creator><creatorcontrib>Ratliff, Patrick ; Nutley, Kaitlin ; Schroeder, William ; Cottingham, Lauren</creatorcontrib><description>What is known and objective
The 4‐factor prothrombin complex concentrate (4F‐PCC) may be used to emergently achieve haemostasis in patients on anticoagulation prior to surgery. Limited data exist using the intraosseous route of administration of 4F‐PCC in patients taking factor Xa inhibitors.
Case description
We describe a case of a 69‐year‐old female receiving oral apixaban that was successfully administered 4F‐PCC using intraosseous access prior to emergent surgery to obtain haemostasis intraoperatively.
What is new and conclusion
Intraosseous access may be a viable route of administration for 4F‐PCC in patients receiving factor Xa inhibitors to achieve haemostasis when necessary.
We present a case of a 69 year old female on chronic oral anticoagulation with apixaban in need of emergent surgery. Adequate peripheral intravenous access could not be obtained in a timely manner necessitating the use of 4‐factor prothrombin complex concentrate via the intraosseous route. The intraosseous route may be a viable option to achieve hemostasis effectively and safely.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.13094</identifier><identifier>PMID: 31805210</identifier><language>eng</language><publisher>England: Hindawi Limited</publisher><subject>Aged ; anticoagulation ; apixaban ; Blood Coagulation Factors - administration & dosage ; Blood Coagulation Factors - therapeutic use ; Factor Xa Inhibitors - administration & dosage ; Factor Xa Inhibitors - therapeutic use ; Female ; haemostasis ; Hemostasis ; Humans ; intraosseous ; Preoperative Period ; Prothrombin ; prothrombin complex concentrate ; Pyrazoles - administration & dosage ; Pyrazoles - therapeutic use ; Pyridones - administration & dosage ; Pyridones - therapeutic use ; Surgery</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2020-06, Vol.45 (3), p.577-579</ispartof><rights>2019 John Wiley & Sons Ltd</rights><rights>2019 John Wiley & Sons Ltd.</rights><rights>Copyright © 2020 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3604-616e8cb7bb1de3f98f15eb3076e1127bda73bbe230652865ab8ad654e2eec6f23</citedby><cites>FETCH-LOGICAL-c3604-616e8cb7bb1de3f98f15eb3076e1127bda73bbe230652865ab8ad654e2eec6f23</cites><orcidid>0000-0002-4688-5073</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.13094$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.13094$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31805210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ratliff, Patrick</creatorcontrib><creatorcontrib>Nutley, Kaitlin</creatorcontrib><creatorcontrib>Schroeder, William</creatorcontrib><creatorcontrib>Cottingham, Lauren</creatorcontrib><title>Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J Clin Pharm Ther</addtitle><description>What is known and objective
The 4‐factor prothrombin complex concentrate (4F‐PCC) may be used to emergently achieve haemostasis in patients on anticoagulation prior to surgery. Limited data exist using the intraosseous route of administration of 4F‐PCC in patients taking factor Xa inhibitors.
Case description
We describe a case of a 69‐year‐old female receiving oral apixaban that was successfully administered 4F‐PCC using intraosseous access prior to emergent surgery to obtain haemostasis intraoperatively.
What is new and conclusion
Intraosseous access may be a viable route of administration for 4F‐PCC in patients receiving factor Xa inhibitors to achieve haemostasis when necessary.
We present a case of a 69 year old female on chronic oral anticoagulation with apixaban in need of emergent surgery. Adequate peripheral intravenous access could not be obtained in a timely manner necessitating the use of 4‐factor prothrombin complex concentrate via the intraosseous route. The intraosseous route may be a viable option to achieve hemostasis effectively and safely.</description><subject>Aged</subject><subject>anticoagulation</subject><subject>apixaban</subject><subject>Blood Coagulation Factors - administration & dosage</subject><subject>Blood Coagulation Factors - therapeutic use</subject><subject>Factor Xa Inhibitors - administration & dosage</subject><subject>Factor Xa Inhibitors - therapeutic use</subject><subject>Female</subject><subject>haemostasis</subject><subject>Hemostasis</subject><subject>Humans</subject><subject>intraosseous</subject><subject>Preoperative Period</subject><subject>Prothrombin</subject><subject>prothrombin complex concentrate</subject><subject>Pyrazoles - administration & dosage</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyridones - administration & dosage</subject><subject>Pyridones - therapeutic use</subject><subject>Surgery</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtKAzEUhoMoWi8bH0AC7oSpucwk06UUrwi6qOshyZzRlM6kJhltwYWP4DP6JKZWXZrND-d8_OF8CB1SMqTpnU7NPA4pJ6N8Aw0oF0XGJCWbaECYGGW5ZHIH7YYwJYQIyfg22uG0JAWjZIDerrvolQsBXB-wqlvb2ZAm0boOuwbnn-8fjTLReTz3Lj5512rbYePa-QwWKTsDq4YIaW8TFR2GFvxjmuLQp_RLrJoIHnswYF9s94jV3C6UVt0-2mrULMDBT-6hh4vzyfgqu727vB6f3WaGC5JnggoojZZa0xp4MyobWoDmRAqglEldK8m1BsaJKFgpCqVLVYsiBwZgRMP4Hjpe96YTnnsIsZq63nfpy4rxkRQ5JXmZqJM1ZXzy4aGp0kWt8suKkmolulqJrr5FJ_jop7LXLdR_6K_ZBNA18GpnsPynqroZ30_WpV8XNIzw</recordid><startdate>202006</startdate><enddate>202006</enddate><creator>Ratliff, Patrick</creator><creator>Nutley, Kaitlin</creator><creator>Schroeder, William</creator><creator>Cottingham, Lauren</creator><general>Hindawi Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><orcidid>https://orcid.org/0000-0002-4688-5073</orcidid></search><sort><creationdate>202006</creationdate><title>Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban</title><author>Ratliff, Patrick ; Nutley, Kaitlin ; Schroeder, William ; Cottingham, Lauren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3604-616e8cb7bb1de3f98f15eb3076e1127bda73bbe230652865ab8ad654e2eec6f23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>anticoagulation</topic><topic>apixaban</topic><topic>Blood Coagulation Factors - administration & dosage</topic><topic>Blood Coagulation Factors - therapeutic use</topic><topic>Factor Xa Inhibitors - administration & dosage</topic><topic>Factor Xa Inhibitors - therapeutic use</topic><topic>Female</topic><topic>haemostasis</topic><topic>Hemostasis</topic><topic>Humans</topic><topic>intraosseous</topic><topic>Preoperative Period</topic><topic>Prothrombin</topic><topic>prothrombin complex concentrate</topic><topic>Pyrazoles - administration & dosage</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyridones - administration & dosage</topic><topic>Pyridones - therapeutic use</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratliff, Patrick</creatorcontrib><creatorcontrib>Nutley, Kaitlin</creatorcontrib><creatorcontrib>Schroeder, William</creatorcontrib><creatorcontrib>Cottingham, Lauren</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratliff, Patrick</au><au>Nutley, Kaitlin</au><au>Schroeder, William</au><au>Cottingham, Lauren</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><addtitle>J Clin Pharm Ther</addtitle><date>2020-06</date><risdate>2020</risdate><volume>45</volume><issue>3</issue><spage>577</spage><epage>579</epage><pages>577-579</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>What is known and objective
The 4‐factor prothrombin complex concentrate (4F‐PCC) may be used to emergently achieve haemostasis in patients on anticoagulation prior to surgery. Limited data exist using the intraosseous route of administration of 4F‐PCC in patients taking factor Xa inhibitors.
Case description
We describe a case of a 69‐year‐old female receiving oral apixaban that was successfully administered 4F‐PCC using intraosseous access prior to emergent surgery to obtain haemostasis intraoperatively.
What is new and conclusion
Intraosseous access may be a viable route of administration for 4F‐PCC in patients receiving factor Xa inhibitors to achieve haemostasis when necessary.
We present a case of a 69 year old female on chronic oral anticoagulation with apixaban in need of emergent surgery. Adequate peripheral intravenous access could not be obtained in a timely manner necessitating the use of 4‐factor prothrombin complex concentrate via the intraosseous route. The intraosseous route may be a viable option to achieve hemostasis effectively and safely.</abstract><cop>England</cop><pub>Hindawi Limited</pub><pmid>31805210</pmid><doi>10.1111/jcpt.13094</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-4688-5073</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2020-06, Vol.45 (3), p.577-579 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_proquest_journals_2397641048 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged anticoagulation apixaban Blood Coagulation Factors - administration & dosage Blood Coagulation Factors - therapeutic use Factor Xa Inhibitors - administration & dosage Factor Xa Inhibitors - therapeutic use Female haemostasis Hemostasis Humans intraosseous Preoperative Period Prothrombin prothrombin complex concentrate Pyrazoles - administration & dosage Pyrazoles - therapeutic use Pyridones - administration & dosage Pyridones - therapeutic use Surgery |
| title | Intraosseous administration of 4‐factor prothrombin complex concentrate prior to emergent surgery after receiving apixaban |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T08%3A20%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraosseous%20administration%20of%204%E2%80%90factor%20prothrombin%20complex%20concentrate%20prior%20to%20emergent%20surgery%20after%20receiving%20apixaban&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Ratliff,%20Patrick&rft.date=2020-06&rft.volume=45&rft.issue=3&rft.spage=577&rft.epage=579&rft.pages=577-579&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/jcpt.13094&rft_dat=%3Cproquest_cross%3E2397641048%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397641048&rft_id=info:pmid/31805210&rfr_iscdi=true |